Abstract 294: Therapeutic Silencing of miR-375 Attenuates Post-MI Inflammatory Response and Left Ventricular Dysfunction in Mice With Myocardial Infarction

2016 ◽  
Vol 119 (suppl_1) ◽  
Author(s):  
Venkata N Garikipati ◽  
Suresh K Verma ◽  
Darukeshwara Jolardarashi ◽  
Maria Cimini ◽  
Jessica Ibetti ◽  
...  

MicroRNAs are known to be dysregulated in the ischemic heart disease and have emerged as potential therapeutic targets for treatment of myocardial infarction (MI). Our preliminary data indicated elevated MicroRNA-375 levels in failing human heart tissue. Therefore, we assessed whether inhibition of the miR-375 using a s.c.-delivered locked nucleic acid (LNA)-modified anti-miR (LNA-antimiR-375) can provide therapeutic benefit in mice with myocardial infarction (MI). After the induction of acute myocardial infarction, mice were treated with either control or LNA based LNA-anti-miR-375, and inflammatory response, cardiomyocyte apoptosis, capillary density and LV functional and structural remodeling changes were evaluated. LNA-anti-miR-375 therapy significantly reduced inflammatory cell infiltration, expression of pro-inflammatory cytokines and cardiomyocyte apoptosis in the myocardium. Further, our cell sorting experiments revealed that within the myocardium, LNA-anti-miR-375 was taken up by cardiomyocytes, endothelial cells and macrophages and repressed miR-375 levels, thereby activating 3-phosphoinositide-dependent protein kinase 1 (PDK-1) and downstream AKT phosphorylation on Thr-308. LNA anti-miR-375 therapy significantly improved LV functions, enhanced neovascularization and reduced infarct size. Corroborating with our in vivo findings, our in vitro studies demonstrated that knock down of miR-375 in macrophages enhanced the expression of PDK-1 and revealed reduced pro-inflammatory cytokines expression following LPS challenge. Taken together, our studies demonstrate that anti miR-375 therapy reduced inflammatory response, cardiomyocyte death, improved LV function and enhanced angiogenesis by targeting multiple cell types via activation of PDK-1/AKT signaling.

2015 ◽  
Vol 117 (suppl_1) ◽  
Author(s):  
Venkata N Garikipati ◽  
Suresh K Verma ◽  
Mohsin Khan ◽  
Anna M Gumpert ◽  
Jibin Zhou ◽  
...  

MicroRNAs are known to be dysregulated in the ischemic heart disease and have emerged as potential therapeutic targets for treatment of myocardial infarction (MI). Recently MicroRNA-375 has been shown to be up-regulated in humans with MI. In this study, we assessed whether inhibition of the miR-375 using an i.v.-delivered locked nucleic acid (LNA)-modified anti-miR (LNA-antimiR-375) can provide therapeutic benefit in mice with pre-existing pathological cardiac remodeling and dysfunction due to myocardial infarction (MI).After the induction of acute myocardial infarction, mice were treated with either control or LNA based miR-375 inhibitor, and inflammatory response, cardiomyocyte apoptosis and LV functional and structural remodeling changes were evaluated. Anti-miR-375 therapy significantly suppressed infiltration of inflammatory cells, expression of proinflammatory cytokines in the myocardium and cardiomyocyte apoptosis. These changes were associated with miR-375 mediated activation of 3-phosphoinositide-dependent protein kinase 1 (PDK-1) and downstream AKT phosphorylation on Thr-308. LNA anti-miR-375 therapy significantly improved LV functions, reduced infarct size, and attenuated infarct wall thinning. Moreover, LNA based miR-375 therapy significantly increased capillary density in the infarcted myocardium. Further, our in vitro studies demonstrated that miR-375 negatively regulates the expression of PDK-1 by directly targeting the 3’UTR of the PDK-1 transcript. Taken together, our studies demonstrate that anti miR-375 therapy suppresses inflammatory response, cardiomyocyte death and contributes to improved LV function and enhanced angiogenesis via activation of PDK-1/AKT signaling.


Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Hidehiro Kaneko ◽  
Toshihisa Anzai ◽  
Kotaro Naito ◽  
Koji Ueno ◽  
Yusuke Jo ◽  
...  

Background: Malignant ventricular arrhythmias, such as sustained ventricular tachycardia and ventricular fibrillation (VT/VF), are fatal complications after acute myocardial infarction (MI) even in the era of reperfusion therapies. We sought to clarify the determinants of VT/VF after reperfused MI. Methods: A total of 528 consecutive acute MI patients, who were treated with primary percutaneous coronary intervention, were divided into 2 groups according to the presence or absence of VT/VF during hospitalization. Serum C-reactive protein (CRP) level and peripheral white blood cell (WBC) count were serially measured for every 24 hours. As a substudy, left ventricular (LV) function and long-term clinical outcome were compared between patients with early (>48 hours after the onset) and late VT/VF (>48 hours). Results: VT/VF was observed in 58 patients (11%). Prior MI and anterior MI are more common in patients with VT/VF than those without. Prevalence of preinfarction angina was less in patients with VT/VF than those without. Peak CRP (14.7±10.1 vs. 8.8±7.1 mg/dl, p< 0.0001), WBC on admission (12833±3513 vs. 10906±4771 /mm 3 , p=0.03) and maximum WBC (14808±5335 vs. 12531±4348 /mm 3 , p=0.009) were higher in patients with VT/VF than those without. Multivariate analysis revealed that prior MI (RR=4.57, p=0.02), absence of preinfarction angina (RR=2.44, p=0.02) and peak serum CRP ≥10 mg/dl (RR=3.37, p=0.003) were independent determinants of VT/VF. Early VT/VF was observed in 49 patients, while late VT/VF in 9 patients. Prevalence of prior MI, preinfarction angina or peak CRP ≥10mg/dl was comparable between early and late VT/VF. LV end-diastolic and end-systolic dimensions are greater in patients with late VT/VF than those with early VT/VF (p< 0.05). Incidence of readmission for heart failure and sudden cardiac death tended to be higher in patients with late VT/VF than those with early VT/VF. Conclusions: VT/VF after reperfused acute MI was associated with prior history of MI, absence of preinfarction angina and increased inflammatory markers. VT/VF occurred in late phase was related to depressed LV function. Lack of ischemic preconditioning, enhanced inflammatory response and subsequent LV remodeling could contribute to the development of VT/VF after MI.


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
Y Ma ◽  
L Ma ◽  
J Ge ◽  
Y Zou

Abstract Background In clinical situation, patients with myocardial infarction (MI) usually suffered from hyperlipidemia, hypertension, renal dysfunction or diabetes as well and the interaction of those risk factors may affect the effectiveness of ACEI. Dendritic cell (DC) is a potent central immunoregulator that orchestrates various types of inflammatory cells in innate and adoptive immunity. The role of DCs in the inflammation of cardiovascular disease is a hotspot of international research. Purpose To investigate the improvement of cardiac remodeling and inflammatory immune response after MI via ACEI regulating DCs and explore that whether the protective effect of ACEI is under the circumstance of hyperlipidemia. Methods In vivo, MI mice models were created via coronary artery ligation. We detected the survival and left ventricular function on day 7 after MI. Tissue samples of the myocardium, spleen, bone marrow and peripheral blood were obtained and assessed for Ang2 concentration, inflammatory cytokines and DCs expression via immunohistochemistry, ELISA, flow cytometry and western blot. In vitro, we treated DCs with ox-LDL+AngIIfor 48 hours simulating the internal environment of MI in ApoE−/− mice to explore the mechanism involved in the DCs maturation and inflammation. Results Under the circumstance of hyperlipidemia, the cardioprotective effect of ACEI is attenuated through regulating DCs maturation and inflammation after MI, including survival rate (Figure 1) and left ventricular function. The number of DCs in cardiac tissue were increased in MI mice with hyperlipidemia (Figure 2), when compared with the WT group. The expression of the maturity phenotype related molecules, such as CD83, on the DCs in spleen were also increased in the ApoE−/− mice. Then, the expressions of inflammatory cytokines, such as IL-6 and TNF-α. In vitro, it was found that the immune maturation and inflammation of DCs could be further induced by ox-LDL on the basis of AngIItreatment, as indicated by the upregulation of CD83 and CD86, the expressions of cytokines and chemokines. Furthermore, ox-LDL could activate the toll-like receptor 4 (TLR4)-myeloid differentiation factor 88 (MyD88) signaling pathway, promoting the phosphorylation of interleukin-1 receptor associated kinase (IRAK)-4 and the nuclear transferring of nuclear factor-kappaB (NF-κB). Conclusion We proved ACEI reduces the recruitment of DCs to the infarct, leading to a higher survival rate and improved function and remodeling through decreased inflammation resulting from immune response after MI. However, this effect was inhibited under the circumstance of hyperlipidemia. TLR4-MyD88 signaling pathway might be the possible molecular mechanism involved in the immune maturation and inflammation of DCs induced by ox-LDL on the basis of AngII. Acknowledgement/Funding the Youth fund of the National Natural Science Foundation of China, Grant 81600280


2018 ◽  
Vol 4 (3) ◽  
pp. 140-146 ◽  
Author(s):  
Mirabela Morariu ◽  
Emese Márton ◽  
András Mester ◽  
Mihaela Rațiu ◽  
Imre Benedek

ABSTRACT Background: The inflammatory response of the immune system plays a major role in the period following an acute myocardial infarction (MI), as it coordinates the formation of the fibrous scar tissue that replaces the infarcted myocardial cells and ultimately leads to healing and remodeling of the affected zone. Along with other pro- and anti-inflammatory cytokines and acute phase proteins, interleukin-6 (IL-6) and C-reactive protein (CRP) are associated with the extent of the infarct size (IS) and may serve as predictors for remodeling and adverse left ventricular (LV) function. Material and methods: A single-center, non-randomized, observational prospective study was conducted, which included 75 patients with primary revascularized ST-elevation myocardial infarction (STEMI). High-sensitivity CRP (hs-CRP) serum levels were determined on day 1 and day 5 following the acute event. IL-6 was also determined on day 1. All patients underwent cardiac magnetic resonance imaging (CMR) at 1-month follow-up with determination of LV function and quantification of the scar tissue using late gadolinium enhancement imaging. The patients were divided into 2 groups based on baseline hs-CRP values. Results: Patients with higher baseline hs-CRP levels presented significantly higher infarct size (p = 0.0003), higher transmural extent (p <0.0001), lower LV ejection fraction (p = 0.0024), end-systolic (p = 0.0021) and end-diastolic (p = 0.0065) volumes. Small IS (<10%) recorded the lowest levels of hs-CRP, while IS >20% presented the highest levels of hs-CRP, at baseline and day 5 (p = 0.4 and 0.001). IL-6 levels were also associated with the magnitude of infarct scar: 2.17 pg/mL for IS <10%, 15.52 pg/mL for IS between 10% and 20%, and 24.52 pg/mL for IS >20%, p = 0.002. Conclusion: hs-CRP and IL-6 serum levels following an MI are correlated with IS, transmurality extent of the scar tissue, as well as with altered systolic and diastolic LV function determined by CMR at 1-month follow-up.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3529-3529
Author(s):  
Heidi M Schmidt ◽  
Eric Kelley ◽  
Adam Straub

Heme crisis drives a number of hemolytic conditions including malaria, sepsis, blood transfusions, and cardiac bypass. Free heme, released from hemoglobin, causes endothelial damage via direct and iron (Fe)-mediated generation of reactive species, as well as activation of endothelial cells and macrophages leading to an inflammatory response. An enzyme that has been shown to have elevated activity in many hemolytic conditions is xanthine oxidase (XO). XO generates hydrogen peroxide (H2O2) as a byproduct of the oxidation of hypoxanthine and xanthine in the final steps of the purine degradation pathway. While XO activity is known to be increased in hemolytic diseases, its exact role has yet to be established. In order to study the role of XO in hemolytic disease, we developed a novel model of heme crisis in which we injected mice with two identical doses of hemin one hour apart and monitored the mice for 24 hours in order to deplete heme scavenging mechanisms before inducing heme crisis. Heme crisis induced damage was evaluated by hemopexin ELISA, plasma XO activity by HPLC, H&E staining of liver, lung, and kidney tissue, qRT-PCR of inflammatory cytokines, and hematological analysis of circulating leukocytes, RBCs, and platelets. To isolate the role of XO, our heme crisis model was repeated; however, prior to hemin injection mice were pretreated with the FDA approved, XO inhibitor febuxostat (10 mg/kg/day) in drinking water. Liver, lung and kidney injury and inflammation was again evaluated with H&E staining, qRT-PCR of inflammatory cytokines, and hematological analysis. In addition, the interaction between heme and XO was explored in vitro using evaluation of hemin degradation via spectrophotometry and computational modeling. We found that mice treated with two doses of 50 μmol/kg hemin had a 92.3% decrease in hemopexin, and a 20-fold increase in plasma XO activity compared to controls. H&E staining showed severe liver hemorrhaging, increased cell infiltration in the lung, and cellular disorganization in the kidney. The pro-inflammatory cytokines, IL-6, TNFα, and IL-1β, were all significantly increased in the liver, lung, and kidney, with IL-6 having the greatest fold change in all three organs. Systemic inflammation was also suggested via significant increases in circulating monocytes and granulocytes. Additionally, hematological analysis showed decreased RBCs and platelets, indicating additional hemolysis and platelet activation. While these markers of injury and inflammation were observed with 50 μmol/kg hemin, lower doses of hemin showed no effect. Together, these results indicate that our heme crisis model mimics the pro-inflammatory state, and organ damage observed in patients during severe hemolysis. Interestingly, when mice were pre-treated with febuxostat, organ damage was observed at lower doses of hemin (25 μmol/kg) compared to untreated mice, as observed by H&E staining. Inhibition of XO also had a significant impact on the inflammatory response. While circulating monocytes were decreased in mice pre-treated with febuxostat, the pro-inflammatory cytokines IL-6, TNFα, and IL-1β, were further exacerbated in the liver, lung, and kidney. This suggests that XO may play a role in mediating the inflammatory response induced by heme crisis. To explore how XO could mediate the inflammatory response we conducted in vitro enzymatic XO experiments with hemin. We found that XO was able to degrade hemin as observed by a decrease in absorbance at 618 nm. Additionally, based on a spectral shift observed when hemin and XO were incubated together, we hypothesized that XO may have the ability to bind hemin. This was further supported by computational modeling in which a potential heme binding site was discovered in the FAD domain of XO with a kd=128 nM. This suggests that XO may have the ability to bind hemin. Thus, during substrate oxidation, H2O2 is produced in the same XO domain of the potential heme binding site, allowing for increased chance of the H2O2 induced heme splitting reaction. We further hypothesize that the uric acid produced by xanthine oxidation may serve as an Fe chelator to scavenge free Fe released by a heme splitting reaction. By creating a microenvironment that can split heme and scavenge Fe, XO may be able to mediate the inflammatory response induced by heme crisis. Disclosures Straub: Bayer Pharmaceuticals: Research Funding.


2021 ◽  
Author(s):  
Ruiting Li ◽  
Xuemei Hu ◽  
Huibin Chen ◽  
Yin Yuan ◽  
Huiling Guo ◽  
...  

Abstract Background The cholinergic anti-inflammatory pathway (CAP) connects the immune response system and the nervous system via the vagus nerve. The key regulatory receptor is the α7-subtype of the nicotinic acetylcholine receptor (α7nAChR), which is localized on the surface of the cells of immune system. CAP has been proved to be effective in suppressing the inflammation responses in acute lung injury (ALI). Dendritic cells (DCs), the important antigen-presenting cells (APCs), also express the α7nAChR. They not only play an important role in immune response priming but also in participating in the pathological process of ALI. Past studies have indicated that reducing the quantity of mature conventional DCs (cDCs) and inhibiting the maturation of pulmonary DCs may prove effective for the treatment of ALI. However, the effects of CAP on maturation, function and quantity of DCs and cDCs in ALI remain unclear. Objective It was hypothesized that the activation of CAP may inhibit the inflammatory response of ALI by regulating maturation, phenotype, and quantity of DCs and cDCs. This can be considered as an important intervention strategy for treating ALI. Methods GTS-21 (GTS-21 dihydrochloride), an α7nAchR agonist was administered in sepsis-induced ALI mice model and LPS-primed bone marrow-derived dendritic cells (BMDCs). The effects of GTS-21 were observed with respect to maturation, phenotype, and quantity of DCs, cDCs, and cDCs2 (type 2 cDCs), and the release of DC-related pro-inflammatory cytokines (such as IL-6, TNF-α, IL-18 IL-1β, IL-12p40, and HMGB1) in vivo and in vitro conditions. Results The results of the present study revealed that, GTS-21 treatment regulated the maturation of DCs and the production of DC-related pro-inflammatory cytokines in vitro and in sepsis-induced ALI mice model, it reduced the quantity of CD11c+MHCII+ cDCs and CD11c+CD11b+ cDCs2 in vivo experiment. Conclusions The activation of CAP contributes to the reduction in the inflammatory response in ALI by regulating maturation, phenotype, and quantity of DCs, cDCs, and cDCs2.


2008 ◽  
Vol 116 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Christian Stumpf ◽  
Sebastian Petzi ◽  
Katrin Seybold ◽  
Gerald Wasmeier ◽  
Martin Arnold ◽  
...  

LV (left ventricular) remodelling is the basic mechanism of HF (heart failure) following MI (myocardial infarction). Although there is evidence that pro-inflammatory cytokines [including TNF-α (tumour necrosis factor-α) and IL-6 (interleukin-6)] are involved in the remodelling process, only little is known about the role of anti-inflammatory cytokines, such as IL-10. As accumulating evidence has revealed that statins possess anti-inflammatory properties, the aim of the present study was to elucidate the effect of atorvastatin on the modulation of the anti-inflammatory cytokine IL-10 and its effect on LV function in rats with HF subsequent to MI. Rats with MI, induced by permanent LAD (left anterior descending) branch coronary artery ligation, were treated for 4 weeks with atorvastatin (10 mg·kg−1 of body weight·day−1 via oral gavage) starting on the first day after induction of MI. Cardiac function was assessed by echocardiography and cardiac catheterization 4 weeks after MI induction. Membrane-bound and soluble fractions of TNF-α, IL-6 and IL-10 protein, the TNF-α/IL-10 ratio, serum levels of MCP-1 (monocyte chemoattractant protein-1) as well as myocardial macrophage infiltration were analysed. Treatment with atorvastatin significantly improved post-MI LV function (fractional shortening, +120%; dP/dtmax, +147%; and LV end-diastolic pressure, −27%). Furthermore atorvastatin treatment markedly decreased the levels of TNF-α, IL-6 and MCP-1, reduced myocardial infiltration of macrophages and significantly increased myocardial and serum levels of the anti-inflammatory cytokine IL-10. Thus the balance between pro-inflammatory and anti-inflammatory cytokines was shifted in the anti-inflammatory direction, as shown by a significantly decreased TNF-α/IL-10 ratio. Atorvastatin ameliorated early LV remodelling and improved LV function in rats with HF subsequent to MI. Our study suggests that the modulation of the balance between pro- and anti-inflammatory cytokines towards the anti-inflammatory cytokine IL-10 is one salutary mechanism underlying how atorvastatin influences post-MI remodelling and thus improves LV function.


Open Heart ◽  
2021 ◽  
Vol 8 (2) ◽  
pp. e001614
Author(s):  
Mohammad R Ostovaneh ◽  
Raj R Makkar ◽  
Bharath Ambale-Venkatesh ◽  
Deborah Ascheim ◽  
Tarun Chakravarty ◽  
...  

BackgroundMost cell therapy trials failed to show an improvement in global left ventricular (LV) function measures after myocardial infarction (MI). Myocardial segments are heterogeneously impacted by MI. Global LV function indices are not able to detect the small treatment effects on segmental myocardial function which may have prognostic implications for cardiac events. We aimed to test the efficacy of allogeneic cardiosphere-derived cells (CDCs) for improving regional myocardial function and contractility.MethodsIn this exploratory analysis of a randomised clinical trial, 142 patients with post-MI with LVEF <45% and 15% or greater LV scar size were randomised in 2:1 ratio to receive intracoronary infusion of allogenic CDCs or placebo, respectively. Change in segmental myocardial circumferential strain (Ecc) by MRI from baseline to 6 months was compared between CDCs and placebo groups.ResultsIn total, 124 patients completed the 6-month follow-up (mean (SD) age 54.3 (10.8) and 108 (87.1%) men). Segmental Ecc improvement was significantly greater in patients receiving CDC (−0.5% (4.0)) compared with placebo (0.2% (3.7), p=0.05). The greatest benefit for improvement in segmental Ecc was observed in segments containing scar tissue (change in segmental Ecc of −0.7% (3.5) in patients receiving CDC vs 0.04% (3.7) in the placebo group, p=0.04).ConclusionsIn patients with post-MI LV dysfunction, CDC administration resulted in improved segmental myocardial function. Our findings highlight the importance of segmental myocardial function indices as an endpoint in future clinical trials of patients with post-MI.Trial registration numberNCT01458405.


2020 ◽  
Vol 35 (3) ◽  
pp. 233-238
Author(s):  
Muflihatul Muniroh

AbstractThe exposure of methylmercury (MeHg) has become a public health concern because of its neurotoxic effect. Various neurological symptoms were detected in Minamata disease patients, who got intoxicated by MeHg, including paresthesia, ataxia, gait disturbance, sensory disturbances, tremors, visual, and hearing impairments, indicating that MeHg could pass the blood-brain barrier (BBB) and cause impairment of neurons and other brain cells. Previous studies have reported some expected mechanisms of MeHg-induced neurotoxicity including the neuroinflammation pathway. It was characterized by the up-regulation of numerous pro-inflammatory cytokines expression. Therefore, the use of anti-inflammatories such as N-acetyl-l-cysteine (NAC) may act as a preventive compound to protect the brain from MeHg harmful effects. This mini-review will explain detailed information on MeHg-induced pro-inflammatory cytokines activation as well as possible preventive strategies using anti-inflammation NAC to protect brain cells, particularly in in vivo and in vitro studies.


Sign in / Sign up

Export Citation Format

Share Document